ISSN (Print): 2328-7322

ISSN (Online): 2328-7314

Website: http://www.sciepub.com/journal/ajcp

Editor-in-chief: Nabil Abdel-Hamid

You are here

Currrent Issue: Volume 4, Number 2, 2016

Article

Role of TACE in Patients with Hepatocellular Carcinoma before Liver Transplantation

1Department of General Surgery, The Thirteenth People's Hospital of Chongqing, Chongqing 400010, China

2Department of Hepatobiliary Surgery, Suining Central Hospital, Suining 629000, China


American Journal of Cancer Prevention. 2016, 4(2), 23-25
doi: 10.12691/ajcp-4-2-1
Copyright © 2016 Science and Education Publishing

Cite this paper:
Cheng Luo, Yakun Wu, Shaoyong Liang. Role of TACE in Patients with Hepatocellular Carcinoma before Liver Transplantation. American Journal of Cancer Prevention. 2016; 4(2):23-25. doi: 10.12691/ajcp-4-2-1.

Correspondence to: Shaoyong  Liang, Department of General Surgery, The Thirteenth People's Hospital of Chongqing, Chongqing 400010, China. Email: 353827514@qq.com

Abstract

Transarterial chemoembolization (TACE) can prevent tumor progression in patients with hepatocellular carcinoma awaiting liver transplantation. This article introduces the effect of TACE before liver transplantation in terms of dropout rate, improvement in overall survival, prediction of survival, and its application as down-stage therapy.

Keywords

References

[1]  Blackburn H, West S. Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer. Cancer Nurs. 2015 Oct 19. [Epub ahead of print].
 
[2]  Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I,et al. “Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation”. World J Gastroenterol 19(34): 5622-5632, Sep 2013.
 
[3]  Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G,et al. “Priority of Candidates With Hepatocellular Carcinoma Awaiting Liver Transplantation Can Be Reduced After Successful Bridge Therapy”, Liver Transpl 17(11):1344-1354, Nov 2011.
 
[4]  Fisher RA, Cotterell AH, Maluf DG, Stravitz RT, Ashworth A, Nakatsuka M, et al. “Adult living donor versus deceased donor liver transplantation:A 10-year prospective single center experience”, Annal of Hepatology 8(4):298-307. Oct 2009.
 
[5]  Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, et al. “Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma”.Clin Transplant, 26(4):359-364, Jul 2012.
 
Show More References
[6]  Fujiki M, Aucejo F, Kim R. “General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int 31(8): 1081-1089, Sep 2011.
 
[7]  Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. “Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation”. World J Gastroenterol 19(43): 7515-7530 Nov 2013.
 
[8]  Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. “Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma”. Liver Transpl 13(2):272-9, Feb 2007.
 
[9]  Decaens T, Roudot-Thoraval F, Bresson-Hadni S, MeyerC, Gugenheim J, Durand F, et al. “Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma”. Liver Transpl 11(7): 767-775, Jul 2005.
 
[10]  Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, et al. “Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival”. J Am Coll Surg 203(4): 411-420, Oct 2006.
 
[11]  Cescon M, Cucchetti A, Ravaioli M, Pinna AD. “Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplant ability and recurrence rate”. J Hepatol 58(3): 609-618, Mar 2013.
 
[12]  Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez Peralvarez ML et al. “Transarterial chemoembolization as neo-adjuvant therapy pre-transplantation in patients with hepatocellular carcinoma”. Liver Int. 33(6):944-949, Jul 2013.
 
[13]  Eswaran SL, Pierce K, Weaver F, Rogers T, Brems JJ, Sontag SJ, et al. “Transarterial Chemoembolization for HCC in Patients With Extensive Liver Transplantation Waiting Times”. Angiology 63(3):206-12, Apr 2012.
 
[14]  Vivanco M, Gabrielli M, Jarufe N, Humeres R, Rios H, Palacios JM, et al. “Bridge therapy in hepatocellular carcinoma before liver transplantation: the experience of two Chilean centers”. Transplant Proc 42(1):296-304 Jan 2010.
 
[15]  Cotoi CG, Khorsandi SE, Pleşea IE, Quaglia A. “Histological aspects of post-TACE hepatocellular carcinoma”. Rom J Morphol Embryol 53(3): 677-682, 2012.
 
[16]  Otto G, Schuchmann M, Hoppe-Lotichius M, Heise M, Weinmann A, Hansen T. “How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions rresponse to TACE?” J Hepatol 59(2): 279-284. Aug 2013.
 
[17]  Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC. “Significance of Tumor Necrosis for Outcome of Patients with Hepatocellular Carcinoma Receiving Locoregional Therapy Prior to Liver Transplantation”. Ann Surg Oncol 18(9): 2416-2426. Sep 2011.
 
[18]  Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, et al. “Hepatocellular Carcinoma: CT for Tumor Response after Transarterial Chemoembolization in Patients Exceeding Milan Criteria—Selection Parameter for Liver Transplantation”. Radiology. 255(1):289-300, Apr 2010.
 
[19]  Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. “Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma as a Bridge to Liver Transplantation: A Retrospective Study”. Int J Hepatol. 974514, Jan 2011.
 
[20]  Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, et al. “Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis”. Clin Transplant 23(21): 61-67, Dec 2009.
 
[21]  Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. “Is the Treatment of Hepatocellular Carcinoma on the Waiting List Necessary?” Liver Transpl 17:S98-108, Oct 2011.
 
[22]  Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. “Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria”. Br J Surg 98(9): 1201-1208, Sep 2011.
 
[23]  Chapman WC , Majella Doyle MB , Stuart JE , Vachharajani N , Crippin JS , Anderson CD, et al. “Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation”. Annals of surgery 248(4):617-642, Oct 2008.
 
Show Less References